KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.

Byoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, Michael Thomas, Shun Lu, Benjamin Besse, Tao Sun, Melissa Martinez, Seema N Sethi, S Martin Shreeve, Alexander I Spira

Future Oncol 18(6) 639-647

PMID34911336
PMCID-
DOI10.2217/fon-2021-0923
发表日期2021-12-16
摘要

摘要

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance EGFR mutations and MET mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for EGFR-mutant non-small-cell lung cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。